1 / 35

Phase II Study of Dasatinib in Advanced Sarcomas SARC009

Phase II Study of Dasatinib in Advanced Sarcomas SARC009. Sarcoma PI: Scott Schuetze GIST PI: Jon Trent Registration and eCRF: CRAB, Seattle Drug Supply: Bristol-Myers Squibb SARC: November 13, 2008. Dasatinib. Small molecule inhibitor of src-family kinases, c-kit and PDGFR

toyah
Download Presentation

Phase II Study of Dasatinib in Advanced Sarcomas SARC009

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Phase II Study of Dasatinib in Advanced SarcomasSARC009 Sarcoma PI: Scott Schuetze GIST PI: Jon Trent Registration and eCRF: CRAB, Seattle Drug Supply: Bristol-Myers Squibb SARC: November 13, 2008

  2. Dasatinib • Small molecule inhibitor of src-family kinases, c-kit and PDGFR • Preclinical data suggested activity in Ewings & osteosarcoma in cell lines • Lack of activity in PPTP pediatric tumor panel • Preclinical data suggests activity in GIST kit and PDGFR mutants not responsive to imatinib

  3. Dasatinib study objectives Primary • Evaluate clinical benefit rate = Choi response or lack of progression for >6 months Secondary • Evaluate 2 and 5 year survival rates • Assess clinical and laboratory toxicities • Collect tumor for tissue microarray • Collect blood samples for drug level and functional inhibition of SRC phosphorylation

  4. Patient Eligibility • Measurable disease • Age > 13 years • weight > 50 kg • ECOG 0-2 • ANC > 1,500, Plt > 75,000 • Creatinine < 2x ULN • Serum calcium, magnesium and potassium > LLN • Pt/PTT < 1.5 x ULN • QTc interval < 450 msec • LVEF > 45% (if prior treatment with anthracycline)

  5. Exclusion/prohibitions • Disease curable by multidisciplinary management • Anti-platelet agents • Anticoagulants • Medications that prolong QT • Active cardiac disease within 6 months • Antacids – PPI, H-2 blockers • IV bisphosphonates • CYP 3A4/5 inducers/inhibitors

  6. Treatment Plan • Tumor tissue submitted to UM (mandatory – all sites) • Negative pregnancy test prior to starting drug (for women of childbearing potential) • CBC weekly 1st month, then monthly • Serum chemistries including magnesium monthly • H&P monthly • ECG baseline & after 1st cycle • Serum sample pre and post dose (selected sites) • Response assessment every 2 months +/- 1 week – on time reporting of response essential

  7. SARC009: Imaging • Imaging every 8 weeks +/- 1 week, same method as baseline • Target lesions at least twice the size of slice thickness on CT • Target lesions on MRI should be at least 1cm • Size = sum of greatest dimension of targets • Density (CT only) = sum of average density of targets

  8. Choi criteria • CR = complete disappearance, no new lesions • PR = >10% reduction in size or >15% decrease in density • Stable = neither CR, PR or PD • PD = >10% increase in size but not >15% decrease in density, or new lesions >1cm, or unequivocal progression of non-target lesions, or clinical deterioration from sarcoma

  9. Dose Adjustment • Dasatinib dosing scheme • 70 mg bid starting dose • 50 mg bid level -1 • 100 mg once daily level -2 • Intolerable grade 2 event, reduce dose without interruption • Significant non-hematologic grade 3 event, hold dose until grade 1 and then restart at reduced dose • Grade 4 non-hematologic event, hold dose until grade 1 and then restart at reduced dose • Grade 3 or 4 neutropenia or thrombocytopenia, hold dose until grade 1 and then restart at reduced dose

  10. Correlative studies • Sub-type specific tissue microarrays – stored at UM, SARC sites will have access • Plasma sample obtained 2 hours after am dose 2-4 weeks after starting, store -20C or below – collection kits provided by SARC • PBMC lysate from sample pre and post am dasatinib dose 2-4 weeks after starting, store -70C or lower – collection kits provided by SARC

  11. UM 39 Penn 21 MD Anderson 11 MGH 15 DFCI 14 City of Hope 19 Fox Chase 17 Stanford 17 Kootenai 16 Johns Hopkins 7 Indiana 6 Emory 8 U Pitt 5 WCI 4 SOC 3 Nebraska 2 Cedars-Sinai 2 Arkansas 1 SARC009: enrollment by site

  12. SARC009: accrual by month

  13. SARC009: cumulative accrual

  14. SARC 009: “Aggressive” sub-types • MFH – 34 OPEN • Osteosarcoma – 27 On hold • Leiomyosarcoma – 48 CLOSED • Liposarcoma – 11 CLOSED • Ewing’s family – 9 1st stage • MPNST – 5 1st stage • Rhabdomyosarcoma – 7 1st stage N = min 9 to max 48 per stratum

  15. SARC009: “Indolent” stratum • ASPS – 2 • Chordoma – 8 • Conventional chondrosarcoma – 19 • Epithelioid sarcoma – 3 • GCT – 0 • Hemangiopericytoma – 10 N = 42 (maximum 116)

  16. SARC009: ineligible • Desmoid/fibromatosis – 1 • Extraskeletal myxoid chondrosarcoma - 1

  17. SARC 009: GIST • Amendment approved May 1, 2008 • Imatinib resistance/intolerance +/- sunitinib • 22 enrolled to date

  18. Prior chemotherapy yes - 76 no - 66 missing – 54 ECOG 0 – 79 1 – 75 2 – 7 missing - 35 Age 13-25y: 15 25-49y: 61 50-74y: 110 75+y: 10 Patient demographics

  19. Adverse events – all grades

  20. Adverse events – all grades

  21. Grade >3 AE

  22. Grade >3 AE

  23. Dasatinib-related SAEs

  24. Dasatinib-related SAEs

  25. Dasatinib dose

  26. Reason off treatment • Progressive disease – 88 • Clinical progression – 9 • Patient withdrew – 9 • Death – 12 • AE, not related – 6 • AE, related – 3 • Physician decision – 0 • Other - 2

  27. SARC009: statistical design • Bayesian / dynamic analysis • Start analysis after enrollment 9-10 per subtype • “aggressive” subtypes - >25% response • “indolent” group – 6 month PFS • > 50% = promising • <30% = inactive • GIST - 6 month PFS • >30% = promising • <10% = inactive

  28. Objective response MFH 4th cycle baseline

  29. Evaluable pts clinical benefit rate(CR/PR + > 6 month SD)

  30. MFH treatment duration

  31. LMS – treatment duration

  32. Osteosarcoma – treatment duration

  33. Liposarcoma – treatment duration

  34. Progression-free survival – “indolent” & GIST

  35. SARC009: summary • Close to completing accrual in “aggressive “ sarcomas • Preliminary results show activity in “MFH” • Results in “indolent” sarcoma allow for continued accrual • GIST too soon to tell • 1/3 require dose reduction • AEs: hematologic, pulmonary, GI, constitutional, pain • Thanks to many investigators for rapid accrual! • Thanks to SARC staff for excellent support!

More Related